Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nadifloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | HPGD | P15428 | 6/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.44 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.44 |
| ▸ | TUBB | P07437 | 1/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.44 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.44 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.44 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nadifloxacin SCHEMBL966009 | 0.98 | LMNA (0.82) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| Nadifloxacin SCHEMBL3818938 | 0.90 | LMNA (1.00) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| Levonadifloxacin SCHEMBL29390463 | 0.90 | LMNA (1.00) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| SCHEMBL16518627 | 0.90 | LMNA (0.85) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| Nadifloxacin SCHEMBL36593 | 0.90 | LMNA (1.00) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| Nadifloxacin SCHEMBL29429713 | 0.90 | LMNA (1.00) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| Levonadifloxacin SCHEMBL36594 | 0.90 | LMNA (1.00) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| Levonadifloxacin SCHEMBL3973065 | 0.89 | LMNA (0.98) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| Levonadifloxacin SCHEMBL3972618 | 0.89 | LMNA (0.98) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 | |
| SCHEMBL15176879 | 0.88 | LMNA (0.81) | LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507519-B2 | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment | WOCKHARDT LIMITED (IN) | 2013-08-13 | — | — | US | disclosed |
| EP-1175217-B8 | (S)-BENZOQUINOLIZINE CARBOXYLIC ACIDS AND THEIR USE AS ANTIBACTERIAL AGENTS | WOCKHARDT LTD (IN) | 2009-03-18 | — | — | EP | disclosed |
| EP-2030620-A1 | (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents | Wockhardt Limited (IN) | 2009-03-04 | — | — | EP | disclosed |
| EP-1175217-B1 | (S)-BENZOQUINOLIZINE CARBOXYLIC ACIDS AND THEIR USE AS ANTIBACTERIAL AGENTS | WOCKHARDT LTD (IN) | 2008-12-03 | — | — | EP | disclosed |
| US-20080108646-A1 | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment | WOCKHARDT LIMITED | 2008-05-08 | — | — | US | disclosed |
| US-20080044466-A1 | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment | WOCKHARDT LIMITED | 2008-02-21 | — | — | US | disclosed |
| US-7247642-B2 | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment | WOCKHARDT LIMITED (IN) | 2007-07-24 | — | — | US | disclosed |
| US-6750224-B1 | USED TO SYSTEMICALLY AND TOPICALLY TREAT BACTERIAL GRAM-POSITIVE, GRAM-NEGATIVE AND ANAEROBIC INFECTIONS, ESPECIALLY RESISTANT MYCOBACTERIAL INFECTIONS AND EMERGING NOSOCOMIAL PATHOGEN INFECTIONS | WOCKHARDT LIMITED (IN) | 2004-06-15 | — | — | US | disclosed |
| US-20030207908-A1 | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment | WOCKHARDT LIMITED (IN) | 2003-11-06 | — | — | US | disclosed |
| EP-1175217-A2 | (S)-BENZOQUINOLIZINE CARBOXYLIC ACIDS AND THEIR USE AS ANTIBACTERIAL AGENTS | Wockhardt Limited (IN) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000068229-A2 | (S)-BENZOQUINOLIZINE CARBOXYLIC ACIDS AND THEIR USE AS ANTIBACTERIAL AGENTS | WOCKHARDT LIMITED (IN) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207908-A1 | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment | RPS27L, HBZ, WIZ | LMNA 3278/4885KDM4E 3032/4885SMN1; SMN2 3554/4885 |
| US-20080108646-A1 | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment | CRYZ, SQLE, SDHA | LMNA 2066/4885KDM4E 3633/4885SMN1; SMN2 4359/4885 |
| US-20080044466-A1 | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment | CRYZ, SQLE, SDHA | LMNA 2066/4885KDM4E 3633/4885SMN1; SMN2 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.